Michael Mortensen
Chief Operating Officer bij BONESUPPORT HOLDING AB
Vermogen: 828 085 $ op 31-03-2024
Profiel
Michael Wrang Mortensen is currently the Director of Development & Supply at Nanovi Radiotherapy A and the EVP of Research, Development & Operations at BONESUPPORT HOLDING AB.
He has a graduate degree from the Technical University of Denmark, a doctorate from the University of Copenhagen, and an MBA from AVT Business School A.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BONESUPPORT HOLDING AB
0.06% | 05-03-2024 | 38 835 ( 0.06% ) | 828 085 $ | 31-03-2024 |
Actieve functies van Michael Mortensen
| Bedrijven | Functie | Begin |
|---|---|---|
| BONESUPPORT HOLDING AB | Chief Operating Officer | 01-12-2021 |
Nanovi Radiotherapy A/S
 Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Corporate Officer/Principal | - |
Opleiding van Michael Mortensen
| Technical University of Denmark | Graduate Degree |
| University of Copenhagen | Doctorate Degree |
| AVT Business School A/S | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BONESUPPORT HOLDING AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Health Technology |
